Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hydrix Limited ( (AU:HYD) ) has shared an announcement.
Hydrix Limited announced that Gyder Surgical, a company within its Ventures portfolio, has secured FDA 510(k) clearance for its GYDER Hip System, marking a pivotal step towards commercialization in the U.S. market. This clearance not only underscores Hydrix’s expertise in medical product development but also boosts Gyder Surgical’s market prospects, particularly in the extensive U.S. market for hip replacement procedures, enhancing the investment value for Hydrix Ventures to $2.65 million.
More about Hydrix Limited
Hydrix Limited is a product innovation company focusing on enhancing health, safety, and well-being. It operates across three business segments: Services, which design and deliver innovative products; Ventures, investing in high-potential MedTech clients; and Medical, distributing disruptive cardiovascular products.
YTD Price Performance: 50.0%
Average Trading Volume: 1,905,078
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$4.09M
See more data about HYD stock on TipRanks’ Stock Analysis page.